27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
To characterize antibodies produced in humans in response to Abeta42 vaccination, we carried out immunohistochemical examinations of the brains of both transgenic mice and human patients with beta-amyloid pathology. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. 2 key findings →
Participants: 104 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Persistence with statin therapy in older patients declines substantially over time, with the greatest drop occurring in the first 6 months of treatment. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On average, persons with mild cognitive impairment had significantly lower scores at baseline in all cognitive domains. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The study presents a technique for automatically assigning a neuroanatomical label to each voxel in an MRI volume using probabilistic information from a manually labeled training set. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2-year rate of infection was 1.20 episodes per 100 resident days, and the hospitalization rate for infection was 0.17 admissions per 100 resident days. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reduced exposure to environmental factors that contribute to cancer risk, tumour-suppressor genes on chromosome 21, or a slower rate of replication or higher likelihood of apoptosis in Down's syndrome cells, could be possible reasons for paucity of cancer in people with Down's syndrome. 4 key findings →
Participants: 17,897 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Two hundred fifteen cases of dementia and 151 cases of AD were diagnosed. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Silent brain infarcts and white matter lesions are frequently seen on magnetic resonance imaging in healthy elderly people and both are associated with an increased risk of stroke and dementia. 5 key findings →
Design: cross-sectional Participants: 1,077 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The average follow-up was 6.0 years. 4 key findings →
Participants: 5,395 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. 1 key finding →
Design: longitudinal study Participants: 77 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The lack of effective predictors of the rate of dementia progression extends to the very earliest stages of the disease, including what is often called MCI. 1 key finding →
Design: longitudinal study Participants: 289 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Incidence of dementia in Italy paralleled that in most industrialized countries. 4 key findings →
Design: longitudinal study Participants: 3,208 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Participants: 108 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Starting in 1991, participants were assessed with the Cognitive Abilities Screening Instrument (CASI) and diagnosed with dementia (including subtype) based on published criteria. 4 key findings →
Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study examined how natural oligomers of human amyloid beta protein are formed, secreted, and affect synaptic function. 4 key findings →
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In its earliest clinical phase, Alzheimer's disease characteristically produces a remarkably pure impairment of memory.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. 5 key findings →
Design: cohort study Participants: 492 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics and an automated voxel-based procedure, is presented and validated in a large data set comprising 110 normal controls and 395 patients with probable Alzheimer's disease (AD) that were studied in eight participating centers. 5 key findings →
Participants: 395 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients with frontotemporal dementia (FTD) with no known diagnosis of ALS or family history of ALS were clinically and electrophysiologically assessed for the presence of ALS. 1 key finding →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The finding that perceived social support is strongly related to well-being but unrelated to burden reinforces the conceptual distinctiveness of the latter two concepts. 3 key findings →
Participants: 243 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Phosphorylation of tau protein at threonine 231 (using full-length tau, 441 amino acids, for the numbering scheme) (p-tau(231)) occurs specifically in postmortem brain tissue of patients with Alzheimer disease (AD) and can be sensitively detected in cerebrospinal fluid (CSF). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the first of five phases in the evolution of beta-amyloidosis Abeta deposits are found exclusively in the neocortex. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
CERAD was funded by the National Institute on Aging with a mandate to standardize assessment in Alzheimer's disease. 5 key findings →
Design: longitudinal study Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Models combining multiple risk factors should refine the prediction of questionable dementia and persistent cognitive impairment, harbingers of dementia. 4 key findings →
Design: cohort study Participants: 48 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →